B8063
BML-210
≥98% (HPLC), powder
别名:
N1-(2-aminophenyl)-N8-phenyl-octanediamide
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H25N3O2
化学文摘社编号:
分子量:
339.43
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
RFLHBLWLFUFFDZ-UHFFFAOYSA-N
SMILES string
Nc1ccccc1NC(=O)CCCCCCC(=O)Nc2ccccc2
InChI
1S/C20H25N3O2/c21-17-12-8-9-13-18(17)23-20(25)15-7-2-1-6-14-19(24)22-16-10-4-3-5-11-16/h3-5,8-13H,1-2,6-7,14-15,21H2,(H,22,24)(H,23,25)
assay
≥98% (HPLC)
form
powder
color
white to very faintly yellow
solubility
DMSO: >20 mg/mL
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
BML-210 is a histone deacetylase inhibitor. Treatment of A549 cells with BML-210 results in a dose-dependent increase in acetylated histone levels (EC50 = 36 μM). In HeLa extracts, the IC50 for inhibition of HDAC activity is 80 μM.
BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.
BML-210 is an HDAC inhibitor.
Features and Benefits
This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
The histone deacetylase inhibitor BML-210 influences gene and protein expression in human promyelocytic leukemia NB4 cells via epigenetic reprogramming
Borutinskaite V and Navakauskiene R
International Journal of Molecular Sciences, 16(8), 18252-18269 (2015)
Veronika Borutinskaitė et al.
International journal of molecular sciences, 16(8), 18252-18269 (2015-08-20)
Today, cancer is understood as an epigenetic as well as genetic disease. The main epigenetic hallmarks of the cancer cell are DNA methylation and histone modifications. Proteins such as histone deacetylases (HDACs) that cause modifications of histones and other proteins
The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines
Savickiene J, et al.
European Journal of Pharmacology, 549(1-3), 9-18 (2006)
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
Jayathilaka N, et al.
Nucleic Acids Research, 40(12), 5378-5388 (2012)
Laura Vidal-Sancho et al.
Molecular neurobiology, 57(11), 4549-4562 (2020-08-07)
People suffering from Huntington's disease (HD) present cognitive deficits. Hippocampal dysfunction has been involved in the HD learning and memory impairment, but proteins leading this dysregulation are not fully characterized. Here, we studied the contribution of the family of transcription
商品
We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持